EVERSANA has added another feature to its ORCHESTRATE platform for the commercialisation of life science products – an ...

Incyte's infringement lawsuit is claiming that Sun Pharma's drug infringes a US patent (No. 9,662,335) it holds on the use of ...

The oral drug – Johnson & Johnson's Balversa (erdafitinib) – will become an option for adults with metastatic or unresectable ...

For Reuters Pharma Europe 2025, pharmaphorum is providing coverage courtesy NAVLIN Daily, a pricing and market access ...

A notice posted by the NIH in February said the agency would slash its funding of indirect costs borne by research teams at ...

Soliris contributed $2.58 billion in global revenues to AZ last year, a 14% drop on the prior year, of which just over $1.4 ...

Much more needs to be done to ensure patient centricity is at the heart of all clinical trials. “Do research with us, not on us,” stated Matthew Zachary, chief executive of US patient advocacy ...

Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ...

The social media landscape is shifting. As X becomes a battleground for increasingly polarised debate, its lesser-known (but strikingly similar) cousin is rapidly gaining traction. A year on from ...

GSK is paying $66 million upfront to license rights to Spero Therapeutics novel antibiotic tebipenem Hbr, unswayed by the FDA's decision earlier this year not to approve the drug for adults with ...

International reliance is a mechanism whereby certain medical devices could access the UK market more quickly if they have already been approved by a comparable regulator, rather than undergoing a ...

Virtual and augmented reality tools have reached a level of maturity to be utilised across various industries. In this article, Ben Hargreaves asks whether there is particular potential for the ...